ARUP's Laboratory Test Directory

Ehlers-Danlos Syndrome Kyphoscoliotic Form, Type VI (PLOD1) Sequencing and Deletion/Duplication : 2005559
[ image for: Patient History for Ehlers-Danlos Kyphoscoliotic Form (Type VI) Testing]
Patient History for Ehlers-Danlos Kyphoscoliotic Form (Type VI) Testing
[ image for: Additional Technical Information]
Additional Technical Information


Mnemonic: EDS-VI FGA

Ordering Recommendation: Diagnostic testing for Ehlers-Danlos syndrome, type VI. Carrier testing for Ehlers-Danlos syndrome, type VI.
Methodology: Polymerase Chain Reaction/Sequencing
Performed: Varies
Reported: Within 21 days
Specimen Required: Collect: Lavender (EDTA), pink (K2EDTA) or yellow (ACD Solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 2 mL)

Storage/Transport Temperature: Refrigerated.

Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Interpretive Data: Background Information for Ehlers-Danlos Syndrome Kyphoscoliotic Form, Type VI (PLOD1) Sequencing and Deletion/Duplication:
Characteristics of Ehlers-Danlos Syndrome Kyphoscoliotic Form, Type VI: Kyphoscoliosis at birth or within the first year of life, severe neonatal hypotonia, thin hyperextensible and bruisable skin, atrophic scarring, joint hypermobility, and scleral fragility leading to increased risk for rupture of the globe. Increased risk for rupture of medium size arteries, and individuals with severe kyphoscoliosis are at increased risk for respiratory compromise.
Incidence: Approximately 1 in 100,000 live births.
Inheritance: Autosomal recessive.
Cause: Lysyl hydroxylase deficiency due to pathogenic PLOD1 (procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase) gene mutations.
Clinical Sensitivity: Not published; however, this test combination is expected to detect the majority of mutations.
Methodology: Bidirectional sequencing of the entire coding region and intron/exon boundaries of the PLOD1 gene. Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large PLOD1 coding region deletions/duplications, including the common 8.3kb duplication of exons 10-16.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Rare diagnostic errors can occur due to primer or probe site mutations. Regulatory region mutations and deep intronic mutations will not be detected. Large deletions/duplications of exon 9 will not be detected; large deletions/duplications of exons 1, 3, 5, and 19 may or may not be detected based on the breakpoints of the rearrangement. The breakpoints of large deletions/duplications will not be determined.



Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.

See Compliance Statement C: www.aruplab.com/CS
CPT Code(s): 81479 x 2
Cross References: EDS6 (Ehlers-Danlos Syndrome Kyphoscoliotic Form, Type VI (PLOD1) Sequencing and Deletion/Duplication) , PLOD1 (Ehlers-Danlos Syndrome Kyphoscoliotic Form, Type VI (PLOD1) Sequencing and Deletion/Duplication)